logo
logo
GKOS stock ticker logo

Glaukos Corporation

NYSE•GKOS
CEO: Mr. Thomas William Burns
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2015-06-25
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Contact Information
One Glaukos Way, Aliso Viejo, CA, 92656, United States
949-367-9600
www.glaukos.com
Market Cap
$6.85B
P/E (TTM)
-35.8
30.1
Dividend Yield
--
52W High
$130.23
52W Low
$73.16
52W Range
77%
Rank47Top 61.9%
3.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$150.57M+0.00%
4-Quarter Trend

EPS

-$0.34+0.00%
4-Quarter Trend

FCF

$0.00+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Strong Net Sales Growth Net sales reached $507.4M in 2025, reflecting substantial $123.9M increase, primarily driven by product adoption.
US Glaucoma Sales Surge US Glaucoma product sales grew approximately 50% to $298.6M, largely due to higher volume and pricing of iDose TR.
Epioxa Regulatory Milestone Secured FDA approval for Epioxa in October 2025 for keratoconus, planning controlled commercial launch in Q1 2026.
Reduced Operating Cash Use Cash used in operating activities was $14.8M in 2025, significantly improving from $61.3M used during the prior year.

Risk Factors

Gross Margin Significantly Compressed Gross margin fell to 56% in 2025, heavily impacted by $112.9M impairment charge related to Photrexa developed technology.
Increased Net Operating Loss Net loss widened 28% to $(187.7M) in 2025, reflecting increased operating expenses and asset impairment charges recorded.
Regulatory Pricing Scrutiny Continued uncertainty exists regarding government pricing programs like MDRP and 340B, potentially reducing realized prices.
Manufacturing Concentration Risk Key implanted products rely on a single San Clemente manufacturing campus, vulnerable to disruption from natural disasters or failures.

Outlook

Epioxa Commercial Launch Planning controlled commercial launch for newly approved Epioxa in Q1 2026, advancing corneal disorder treatment options.
Increased R&D Expenditures Expect R&D expenses to increase as the company advances pipeline products through clinical trials and regulatory submissions.
New Manufacturing Expansion Commencing construction of a new 200,000 square foot R&D and manufacturing facility in Huntsville, Alabama, starting in 2026.
iDose TR Utilization Growth Anticipate increased iDose TR utilization as reimbursement processes stabilize and become consistent across all Medicare Administrative Contractors.

Peer Comparison

Revenue (TTM)

OSCR stock ticker logoOSCR
$11.70B
+27.5%
BLCO stock ticker logoBLCO
$5.20B
+7.7%
BRKR stock ticker logoBRKR
$3.44B
+2.1%

Gross Margin (Latest Quarter)

BLCO stock ticker logoBLCO
99.9%
-1.0pp
ARWR stock ticker logoARWR
97.6%
+50.6pp
PTGX stock ticker logoPTGX
94.9%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ARWR$9.88B48.836.1%19.5%
GKOS$6.85B-35.8-26.5%11.5%
ACLX$6.73B-28.3-55.4%15.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.7%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026
|
EPS:-$0.27
|
Revenue:$136.98M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data